Sars Cov Spike Protein Nmr
Lab Reagents
Human IgG antibody Laboratories manufactures the sars cov spike protein nmr reagents distributed by Genprice. The Sars Cov Spike Protein Nmr reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact Spike Protein. Other Sars products are available in stock. Specificity: Sars Category: Cov Group: Spike Protein
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680-050 | EpiGentek | 50 ul | Ask for price |
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680-100 | EpiGentek | 100 ul | EUR 882.2 |
SARS-CoV-2 Spike Monoclonal Antibody |
|||
A73664 | EpiGentek |
|
|
SARS-CoV-2 Spike RBD Nanobody |
|||
A73680 | EpiGentek |
|
|
Sars-Cov, Spike (N-Term) Recom Protein |
|||
abx060657-1mg | Abbexa | 1 mg | EUR 2247.6 |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-10 | Biovision | 10µg | EUR 187.2 |
Recombinant Coronavirus Spike Protein (SARS-CoV S2) |
|||
P1519-50 | Biovision | 50µg | EUR 661.2 |
SARS-CoV-2 (COVID-19) Spike Recombinant Protein |
|||
20-233 | ProSci | 0.1 mg | EUR 726.9 |
Description: SARS-CoV-2 (COVID-19) Spike Recombinant Protein |
SARS-CoV-2 (COVID-19) Spike Recombinant Protein |
|||
11-073 | ProSci | 0.1 mg | EUR 695.4 |
Description: May down-regulate host tetherin (BST2) by lysosomal degradation, thereby counteracting its antiviral activity. |
SARS-CoV-2(COVID-19) Spike Recombinant Protein |
|||
10-411 | ProSci | 0.1 mg | EUR 714.3 |
Description: Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, angiotensin-converting enzyme 2, DPP4, CEACAM etc.. The spike (S) glycoprotein of coronaviruses is known to be essential in the binding of the virus to the host cell at the advent of the infection process. Most notable is severe acute respiratory syndrome (SARS). The severe acute respiratory syndrome-coronavirus (SARS-CoV) spike (S) glycoprotein alone can mediate the membrane fusion required for virus entry and cell fusion. It is also a major immunogen and a target for entry inhibitors. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity. |
Recombinant Coronavirus Spike Protein (SARS-CoV-2; ECD) |
|||
P1533-10 | Biovision | 10 µg | EUR 235.2 |
Recombinant Coronavirus Spike Protein (SARS-CoV-2; ECD) |
|||
P1533-50 | Biovision | 50 µg | EUR 709.2 |
Recombinant SARS-CoV Spike protein [GST] (37 kDa) |
|||
VAng-Wyb8620-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS-CoV C-terminal of the Spike protein (37 kDa), recombinant protein from E. coli, 1 mg/mL. |
Recombinant SARS-CoV Spike protein [GST] (38 kDa) |
|||
VAng-Wyb8621-inquire | Creative Biolabs | inquire | Ask for price |
Description: SARS-CoV middle region of the Spike protein (38 kDa), recombinant protein from E. coli, 1 mg/mL. |
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-002mg | ProSci | 0.02 mg | EUR 206.18 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
SARS-CoV-2 (COVID-19) Spike Antibody |
|||
3525-01mg | ProSci | 0.1 mg | EUR 523.7 |
Description: Coronavirus disease 2019 (COVID-19), formerly known as 2019-nCoV acute respiratory disease, is an infectious disease caused by SARS-CoV-2, a virus closely related to the SARS virus (1). The disease is the cause of the 2019–20 coronavirus outbreak (2). The structure of 2019-nCoV consists of the following: a Spike protein (S), hemagglutinin-esterease dimer (HE), a membrane glycoprotein (M), an envelope protein (E) a nucleoclapid protein (N) and RNA. Coronavirus invades cells through Spike (S) glycoproteins, a class I fusion protein. It is the major viral surface protein that coronavirus uses to bind to the human cell surface receptor. It also mediates the fusion of host and viral cell membrane, allowing the virus to enter human cells and begin infection (3). The spike protein is the major target for neutralizing antibodies and vaccine development (4). The protein modeling suggests that there is strong interaction between Spike protein receptor-binding domain and its host receptor angiotensin-converting enzyme 2 (ACE2), which regulate both the cross-species and human-to-human transmissions of COVID-19 (5). The recent study has shown that the SARS-CoV-2 spike protein binds ACE2 with higher affinity than SARS-CoV spike protein (6). |
Anti-SARS-CoV-2 Spike S1 Antibody |
|||
A3000-50 | Biovision | 50 µg | EUR 502.8 |